Core Viewpoint - The market anticipates TransUnion (TRU) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - TransUnion is expected to post quarterly earnings of $1.03 per share, reflecting a year-over-year increase of +6.2% [3]. - Revenues are projected to reach $1.14 billion, marking a 9.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.47% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for TransUnion is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.61%, suggesting a bullish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [9]. Historical Performance - TransUnion has consistently beaten consensus EPS estimates, achieving this in the last four quarters [13]. - In the last reported quarter, TransUnion exceeded expectations by delivering earnings of $1.10 per share against an expected $1.04, resulting in a surprise of +5.77% [12]. Conclusion - TransUnion is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings results when making investment decisions [16].

Core Viewpoint - The market anticipates West Pharmaceutical Services (WST) to report a year-over-year earnings increase driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Group 1: Earnings Expectations - The consensus estimate for quarterly earnings is $1.83 per share, reflecting a year-over-year change of +0.6% [3] - Expected revenues are projected at $794.26 million, which is a 6.1% increase from the same quarter last year [3] Group 2: Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - West Pharmaceutical's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.78%, suggesting a bearish sentiment among analysts [11] Group 3: Historical Performance - In the last reported quarter, West Pharmaceutical exceeded the expected earnings of $1.67 per share by delivering $1.96, resulting in a surprise of +17.37% [12] - The company has beaten consensus EPS estimates in all four of the last quarters [13] Group 4: Market Sentiment and Stock Movement - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - Despite a potential earnings beat, other factors may influence stock performance, making it essential to consider broader market conditions [14][16]

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

Wall Street expects a year-over-year decline in earnings on lower revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] Zacks Style Scores - The Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow to find attractive investment opportunities [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify companies with sustainable growth potential [4] Momentum Score - The Momentum Style Score assists investors in capitalizing on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes to determine optimal entry points [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth forecasts, and promising momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8] Stock Selection Strategy - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential success, while stocks with lower ranks should also have strong Style Scores to mitigate risks [9][10] Company Spotlight: Gentex Corporation - Gentex Corporation, based in Zeeland, MI, specializes in automatic-dimming rear-view mirrors, fire protection products, and dimmable aircraft windows, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of A [11] - Gentex has a Momentum Style Score of A, with shares increasing by 2.1% over the past four weeks, and two analysts have raised their earnings estimates for fiscal 2026, increasing the Zacks Consensus Estimate by $0.04 to $1.97 per share, alongside an average earnings surprise of +3.8% [12]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence in investing [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score assesses a company's financial strength and future outlook based on projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stocks with strong value, growth forecasts, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary stock-rating model that uses earnings estimate revisions to assist in building a successful portfolio [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have A or B Scores to ensure potential upside [10] Company Spotlight: Prosperity Bancshares - Prosperity Bancshares, based in Houston, TX, operates through its bank subsidiary and is currently rated 3 (Hold) with a VGM Score of B [12] - The company has a Momentum Style Score of A, with shares increasing by 4% over the past four weeks, and an upward revision in earnings estimates for fiscal 2026 [13]

Company Overview - Plexus Corp., founded in 1979 and based in Neenah, WI, is a leading provider of electronic contract manufacturing services to original equipment manufacturers (OEMs) across various industries, including Healthcare/Life Sciences, Industrial, and Aerospace/Defense sectors [11]. Investment Ratings - Plexus Corp. currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating a solid overall performance [11]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of A, forecasting a year-over-year earnings growth of 2.4% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, two analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.12 to $7.61 per share [12]. - Plexus Corp. has demonstrated an average earnings surprise of +8.9%, suggesting a positive trend in earnings performance [12].

Company Overview - TD SYNNEX is a leading global IT distributor and solutions aggregator, providing a comprehensive range of technology distribution, logistics, and integration services [11] - The company was rebranded from SYNNEX Corporation to TD SYNNEX in September 2021 following its merger with Tech Data Corporation, which significantly expanded its global reach and vendor partnerships [11] Investment Ratings - TD SYNNEX currently holds a Zacks Rank of 3 (Hold) with a VGM Score of A, indicating a solid position in the market [12] - The company has a Growth Style Score of A, forecasting year-over-year earnings growth of 9.3% for the current fiscal year [12] Earnings Estimates - In the last 60 days, four analysts revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing by $0.06 to $14.42 per share [12] - TD SYNNEX boasts an average earnings surprise of +7.8%, suggesting a strong performance relative to expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TD SYNNEX is recommended as a potential top pick for growth investors [13]

Company Performance - Biofrontera Inc. (BFRI) has returned 55.7% year-to-date, significantly outperforming the average return of 4.3% for Medical companies [4] - The Zacks Consensus Estimate for BFRI's full-year earnings has increased by 700% over the past 90 days, indicating a strong improvement in analyst sentiment and earnings outlook [3] - Biofrontera Inc. is part of the Medical - Biomedical and Genetics industry, which has an average year-to-date return of 21%, further highlighting BFRI's superior performance [5] Industry Context - The Medical sector consists of 928 individual stocks and is currently ranked 10 in the Zacks Sector Rank [2] - The Medical - Biomedical and Genetics industry includes 449 companies and is ranked 90 in the Zacks Industry Rank [5] - Brookdale Senior Living (BKD), another Medical stock, has returned 38.1% year-to-date and is part of the Medical - Nursing Homes industry, which has a year-to-date return of +7.2% [4][6]

Core Viewpoint - Veracyte (VCYT) has experienced a significant downtrend, with a 20% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - VCYT's current RSI reading is 28.44, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - Analysts covering VCYT have shown strong consensus in raising earnings estimates, with a 0.8% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - VCYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].